2,2,2-Trifluoroethyl-thiadiazines: a patent evaluation of WO2016023927

References

• Korolev IO. Alzheimer’s disease: a clinical and basic science review. Med Student Res J. 2014;4:24–33.
   Google Scholar
• Bird TD. Alzheimer disease overview. In: Pagon RA, Adam MP, Ardinger HH, et al. editors. GeneReviews® [Internet]. Seattle (WA): University of Washington; Seattle; 1993-2016 [updated 2015 Sep 24; cited 1998 Oct 23]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1161/
   Google Scholar
• Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol, Neurosurg Psychiatry. 1999;66(2):137–147.
   PubMed Web of Science ®Google Scholar
• Birks JS. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1): Art. No.: CD005593. DOI:10.1002/14651858.CD005593
   Web of Science ®Google Scholar
• Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211–225.
   PubMed Web of Science ®Google Scholar
• Winslow BT, Onysko MK, Stob CM, et al. Treatment of Alzheimer disease. Am Fam Physician. 2011;83(12):1403–1412.
   PubMed Web of Science ®Google Scholar
• Massoud F, Leger GC. Pharmacological treatment of Alzheimer disease. Can J Psychiatry. 2011;56(10):579–588.
   PubMed Web of Science ®Google Scholar
• Ströhle A, Schmidt DK, Schultz F, et al. Drug and exercise treatment of Alzheimer disease and mild cognitive impairment: a systematic review and meta-analysis of effects on cognition in randomized controlled trials. Am J Geriatr Psychiatry. 2015;23(12):1234–1249.
   PubMed Web of Science ®Google Scholar
• Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis. PLoS ONE. 2015;10:(4): e0123289. DOI:10.1371/journal.pone.0123289.
   Web of Science ®Google Scholar
• Plosker GL. Memantine extended release (28 mg once daily): a review of its use in Alzheimer’s disease. Drugs. 2015;75(8):887–897.
   PubMed Web of Science ®Google Scholar
• Kumar A, Singh A, Ekavali. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67(2):195–203.
   PubMed Web of Science ®Google Scholar
• Wang X, Blanchard J, Grundke-Iqbal I, et al. Memantine attenuates Alzheimer’s disease-like pathology and cognitive impairment. PLoS ONE. 2015;10(12):e0145441. DOI:10.1371/journal.pone.0145441.
   PubMed Web of Science ®Google Scholar
• Bishara D, Sauer J, Taylor D. The pharmacological management of Alzheimer’s disease. Prog Neurol Psychiatry. 2015;19(4):9–16.
   Google Scholar
• Salomone S, Caraci F, Leggio GM, et al. New pharmacological strategies for treatment of Alzheimer’s disease: focus on disease-modifying drugs. Br J Clin Pharmacol. 2012;73(4):504–517.
   PubMed Web of Science ®Google Scholar
• Ambure P, Roy K. Advances in quantitative structure-activity relationship models of anti-Alzheimer’s agents. Expert Opin Drug Discov. 2014;9(6):697–723.
   PubMed Web of Science ®Google Scholar
• Peters O, Shelkovnikova TA, Tarasova T, et al. Chronic administration of dimebon does not ameliorate Aβ pathology in 5xFAD transgenic mice. J Alzheimer’s Dis. 2013;36:589–596.
   PubMed Web of Science ®Google Scholar
• Siemers ER, Sundell KL, Carlson C, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients. Alzheimer’s & Dementia. 2016;12(2):110–120.
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–356.
   PubMed Web of Science ®Google Scholar
• Vassar R. The beta-secretase, BACE: a prime drug target for Alzheimer’s disease. J Mol Neurosci. 2001;17(2):157–170.
   PubMed Web of Science ®Google Scholar
• Vassar R. BACE1: the beta-secretase enzyme in Alzheimer’s disease. J Mol Neurosci. 2004;23(1–2):105–114.
   PubMed Web of Science ®Google Scholar
• Vassar R. β-Secretase (BACE) as a drug target for Alzheimer’s disease. Adv Drug Deliv Rev. 2002;54(12):1589–1602.
   PubMed Web of Science ®Google Scholar
• Decourt B, Sabbagh MN. BACE1 as a potential biomarker for Alzheimer’s disease. J Alzheimers Dis. 2011;24(Suppl 2):53–59.
   PubMed Web of Science ®Google Scholar
• Cole SL, Vassar R. The Alzheimer’s disease β-secretase enzyme, BACE1. Mol Neurodegener. 2007;2(1):22.
   PubMed Web of Science ®Google Scholar
• Sathya M, Premkumar P, Karthick C, et al. BACE1 in Alzheimer’s disease. Clinica Chimica Acta. 2012;414:171–178.
   PubMed Web of Science ®Google Scholar
• Yan R, Vassar R. Targeting the β-secretase BACE1 for Alzheimer’s disease therapy. Lancet Neurol. 2014;13(3):319–329.
   PubMed Web of Science ®Google Scholar
• Ghosh AK. Aspartic acid proteases as therapeutic targets. In: Mannhold R, Kubinyi H, Folkers G, editors. Methods and principles in medicinal chemistry. Vol. 45. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2010. p. 441–479.
   Google Scholar
• Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10(9):698–712.
   PubMed Web of Science ®Google Scholar
• Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature. 2012;488(7409):96–99.
   PubMed Web of Science ®Google Scholar
• Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease. Alzheimer’s Res Ther. 2014;6(9):89.
   PubMedGoogle Scholar
• Ghosh AK, Shin D, Downs D, et al. Design of potent inhibitors for human brain memapsin 2 (β-secretase). J Am Chem Soc. 2000;122(14):3522–3523.
   Web of Science ®Google Scholar
• Hong L, Turner RT, Koelsch G, et al. Crystal structure of memapsin 2 (β-Secretase) in complex with an inhibitor OM00-3†. Biochemistry. 2002;41:10963–10967.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Brindisi M, Tang J. Developing β‐secretase inhibitors for treatment of Alzheimer’s disease. J Neurochem. 2012;120(s1):71–83.
   PubMed Web of Science ®Google Scholar
• Stachel SJ. Progress toward the development of a viable BACE-1 inhibitor. Drug Dev Res. 2009;70:101–110.
   Web of Science ®Google Scholar
• Probst G, Xu YZ. Small-molecule BACE1 inhibitors: a patent literature review (2006–2011). Expert Opin Ther Pat. 2012;22:511–540.
   PubMed Web of Science ®Google Scholar
• Evin G, Lessene G, Wilkins S. BACE inhibitors as potential drugs for the treatment of Alzheimer’s disease: focus on bioactivity. Recent Pat CNS Drug Discov. 2011;6:91–106.
   PubMedGoogle Scholar
• Wang YS, Strickland C, Voigt JH, et al. Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel μM leads for the development of nM BACE-1 (β-site APP cleaving enzyme 1) inhibitors. J Med Chem. 2010;53(3):942–950.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Sun ZY, Ye Y, et al. Discovery of cyclic acylguanidines as highly potent and selective β-site amyloid cleaving enzyme (BACE) inhibitors: part i - inhibitor design and validation. J Med Chem. 2010;53(3):951–965.
   PubMed Web of Science ®Google Scholar
• Stamford A, Strickland C. Inhibitors of BACE for treating Alzheimer’s disease: a fragment-based drug discovery story. Curr Opin Chem Biol. 2013;17(3):320–328.
   PubMed Web of Science ®Google Scholar
• Stamford AW, Scott JD, Li SW, et al. Discovery of an orally available, brain penetrant BACE1 inhibitor that affords robust CNS Aβ reduction. ACS Med Chem Lett. 2012;3(11):897–902.
   PubMed Web of Science ®Google Scholar
• Forman M, Tseng J, Palcza J, et al. The novel BACE inhibitor MK-8931 dramatically lowers CSF Aβ peptides in healthy subjects: results from a rising single dose study (PL02. 004). Neurology. 2012;78(1 Supplement):PL02–004.
   Google Scholar
• Yan R. Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs. Transl Neurodegener. 2016;5.1:1.
   Web of Science ®Google Scholar
• Evin G. Future therapeutics in Alzheimer’s disease: development status of BACE inhibitors. BioDrugs. 2016;30(3):173–194.
   PubMed Web of Science ®Google Scholar
• Chambers RK, Khan TA, Olsen DB, et al. Synthesis of amino heterocycle aspartyl protease inhibitors. Org Biomol Chem. 2016;14:4970–4985.
   PubMed Web of Science ®Google Scholar
• Anselm L, Bartels B, Dolente C, et al. (F. Hoffmann–La Roche AG) 2,2,2-Trifluoroethylthiadiazines. WO2016023927. 2016.
   Google Scholar
• Youn JH, Herrmann R. A simple and efficient preparation of sulfinyl chlorides from disulfides and sulfuryl chloride. Tetrahedron Lett. 1986;27(13):1493–1494.
   Web of Science ®Google Scholar
• Tang TP, Ellman JA. The tert-butanesulfinyl group: an ideal chiral directing group and Boc-surrogate for the asymmetric synthesis and applications of β-Amino acids. J Org Chem. 1999;64(1):12–13.
   PubMed Web of Science ®Google Scholar
• Moody CJ. Polyoxa, polythia and polyaza six-membered ring systems. In: Comprehensive heterocyclic chemistry. Vol. 3. Chapter 2.28. Katritzky AR, Rees CW editors Oxford: Pergamon Press; 1984. p. 1039–1086.
   Google Scholar
• Smalley RK. 1,2,4-Oxadiazines and 1,2,4-thiadiazines. In: Comprehensive heterocyclic chemistry II. Vol. 6. Chapter 6.14. Boulton AJ editor. Oxford: Elsevier; 1996. p. 645–680.
   Google Scholar
• Norris P. 1,2,4-Oxadiazines and 1,2,4-Thiadiazines. In: Comprehensive heterocyclic chemistry III. Vol. 9. Chapter 9.05. Katritzky AR, Ramsden CA, Scriven EFV, et al. editors. Oxford: Elsevier; 2008. p. 301–343.
   Google Scholar
• Bartels B, Dolente C, Guba W, et al. (F. Hoffmann–La Roche AG). Pyridyl-triazabicycles. WO 2016012422 A1. 2016.
   Google Scholar
• Guba W, Haap W, Kuglstatter A, et al. (F. Hoffmann–La Roche AG). 5-Aryl-1-imino-1-oxo-[1,2,4]thiadiazines. WO 2015091595 A1. 2015.
   Google Scholar
• Evin G, Barakat A. Critical analysis of the use of β-site amyloid precursor protein-cleaving enzyme 1 inhibitors in the treatment of Alzheimer’s disease. Degener Neurol Neuromuscul Dis. 2014;4:1–19.
   Google Scholar